Xultophy® Demonstrates Similar Glucose Control with Reduced Risk of Hypoglycaemia and a Superior Weight Profile Compared to Basal-Bolus Therapy
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced new phase 3b trial (DUAL VII) results with Xultophy® (IDegLira). Xultophy® is a once-daily, single injection fixed combination ...